Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2002

View Archived Issues

Abreva approved for OTC sale in Canada, Korea

Photofrin sNDA filed, orphan drug status granted, in high-grade dysplasia in Barrett's esophagus

Sankyo and Ube present antibacterial quinolizinones

New prenyltransferase inhibitors in early development at Merck

Fujisawa patents series for use in urinary incontinence

Novel calcilytic compounds and their use described in GSK patent

Aventis Pharma presents novel NHE3 inhibitors

VLA-4 antagonists with potential in asthma and inflammation

Antitumor xanthone compounds obtained from Streptomyces

Heat shock protein coinducer BRX-220 effective in rat model of acute pancreatitis

Effects of new SERM on bone, cholesterol and uterus compared to EE2 and levormeloxifene

Endogenous neuroprotective factor identified by Japanese group

Final analysis of phase III data for Zamyl in AML

Survival benefit for long-term atrasentan in HRPCa

Delay in PSA and clinical progression of prostate cancer achieved using Prostvac

KRX-211 has potential in septic shock

Neurontin receives FDA approval for postherpetic neuralgia

HIV immune responses induced by Remune plus CpG adjuvant in monkeys

Phase I study of aplidine as a three-hour infusion in solid tumor patients

Phase I/II enrollment completed for HuMax-IL-15 in rheumatoid arthritis

Endocyte licenses Galenica's GP-0100 for vitamin-based cancer treatments

Vion reprioritizes development program

Interim data announced from Neotrofin pilot study in Parkinson's disease

CPMP recommends approval of Visudyne in occult subfoveal CNV secondary to AMD

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...